Solid Biosciences, Inc. (SLDB)
10.10
+0.38
(+3.91%)
USD |
NASDAQ |
Aug 27, 14:42
Solid Biosciences Total Liabilities (Quarterly) : 46.50M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 46.50M |
| March 31, 2026 | 48.76M |
| December 31, 2025 | 52.53M |
| September 30, 2025 | 55.97M |
| June 30, 2025 | 50.00M |
| March 31, 2025 | 49.44M |
| December 31, 2024 | 51.42M |
| September 30, 2024 | 44.80M |
| June 30, 2024 | 37.74M |
| March 31, 2024 | 37.96M |
| December 31, 2023 | 38.46M |
| September 30, 2023 | 40.37M |
| June 30, 2023 | 40.99M |
| March 31, 2023 | 45.80M |
| December 31, 2022 | 48.59M |
| September 30, 2022 | 41.20M |
| June 30, 2022 | 46.26M |
| March 31, 2022 | 22.04M |
| December 31, 2021 | 24.17M |
| September 30, 2021 | 25.62M |
| Date | Value |
|---|---|
| June 30, 2021 | 27.92M |
| March 31, 2021 | 32.28M |
| December 31, 2020 | 39.08M |
| September 30, 2020 | 18.29M |
| June 30, 2020 | 17.25M |
| March 31, 2020 | 17.50M |
| December 31, 2019 | 23.42M |
| September 30, 2019 | 22.40M |
| June 30, 2019 | 19.81M |
| March 31, 2019 | 21.12M |
| December 31, 2018 | 14.41M |
| September 30, 2018 | 11.74M |
| June 30, 2018 | 9.178M |
| March 31, 2018 | 10.29M |
| December 31, 2017 | 11.27M |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | 7.892M |
| December 31, 2016 | 6.873M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Agenus, Inc. | 378.54M |
| Amgen, Inc. | 83.95B |
| Anika Therapeutics, Inc. | 46.19M |
| BioCryst Pharmaceuticals, Inc. | 1.012B |
| Imunon, Inc. | 10.80M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 420.58M |
| Shareholders Equity (Quarterly) | 374.08M |
| Debt to Equity Ratio | 0.0539 |
| Current Ratio | 13.82 |
| Net Debt Paydown Yield | 0.07% |